Choosing a strain or cell line is one of those decisions that looks technical at first, but can become surprisingly strategic later.
The right expression system can influence yield, product quality, downstream processing, scalability and cost. But there is another question that is easier to overlook: will the platform you choose today limit where you can manufacture tomorrow?
For biotech teams comparing mammalian cell lines, microbial strains and different development platforms, here are six questions worth asking before committing.
Is the highest-producing cell line really the best one?
Not necessarily.
A high titer looks attractive, but upstream productivity is only one part of the equation. Product quality, aggregation, folding, glycosylation, impurity profile and downstream recovery can change the economics of the entire process.
A lower-producing clone that gives you a cleaner and more consistent product may ultimately deliver a better manufacturing process.
The goal is therefore not simply maximum expression. It is the best overall fit for the molecule and its future biologics manufacturing requirements.
How much should the molecule influence expression system selection?
A lot.
The molecule should come first, then the platform.
Complex proteins requiring specific post-translational modifications may naturally point toward mammalian systems such as CHO or HEK. Other recombinant proteins may be better suited to microbial hosts such as E. coli, Pichia pastoris or other yeast and fungal systems.
The important point is that there should not be a default answer.
Good cell line selection starts by understanding the molecule, the target quality profile, the required scale and the future manufacturing strategy.
Can choosing a cell line affect which CDMO I can use later?
Yes, and this is where the decision becomes particularly important.
Some proprietary cell lines or microbial platforms are offered under licensing models that may include royalties, access fees or specific manufacturing conditions.
In certain cases, using the platform can make it necessary, or commercially advantageous, to continue manufacturing with the organization that owns the technology or within its approved network.
That is not automatically a problem. But it should be understood before development begins, rather than discovered when the program is ready for GMP manufacturing.
What should I check before accepting a platform licence?
Look beyond the initial access fee.
The key questions are what happens when the product progresses.
Can you transfer the cell line to another CDMO? Are there commercial royalties? Are there restrictions on manufacturing sites? Who owns the clone and generated cell banks? Does the licence change once you move from development to clinical or commercial manufacturing?
These conditions can have a much greater impact on the program than the initial cost of cell line development.
A technically strong platform is only attractive if its long-term conditions also fit your strategy.
What if I do not want my cell line choice to determine my future manufacturer?
Then platform flexibility should become part of the selection criteria from the beginning.
At 53Biologics, we do not force every project into a proprietary cell line. Instead, we work with a network of specialized partners and can evaluate different mammalian and microbial expression systems according to the needs of each biological product.
This gives clients the opportunity to compare platforms rather than accepting a single predefined solution.
More importantly, choosing a platform through our partner network does not oblige the client to manufacture with 53Biologics.
If the client later decides that another manufacturing route makes more sense, that decision remains theirs. Any licensing conditions associated with a specific third-party platform are reviewed transparently from the beginning.
So, what does a good cell line selection strategy actually look like?
It should balance science with long-term freedom.
The right strain or cell line should be capable of producing the required product quality, supporting scalable manufacturing and fitting the expected cost and development timeline.
But it should also make sense commercially.
Before selecting a platform, sponsors should understand not only what it can produce, but also what rights and restrictions come with it.
That is particularly important for programs expected to progress from early development into GMP and potentially commercial production.
Find your best fit, and keep your options open
Expression system selection should enable the program, not quietly restrict its future.
At 53Biologics, we help biotech teams evaluate different microbial strains and mammalian cell lines according to the molecule, the process and the long-term manufacturing strategy. Our approach is built around finding the best fit rather than promoting a single proprietary platform.
Clients can continue with us through process development, analytics, GMP manufacturing and fill and finish, or choose another manufacturing partner later.
The important thing is that the decision remains informed, transparent and yours.
Considering different cell lines or microbial strains for your biologic? Contact the 53Biologics team and let us help you compare the scientific and manufacturing implications before you commit.
About 53Biologics:
53Biologics is the end-to-end biologics CDMO built to keep progress moving. We combine scientific expertise, integrated in-house capabilities and a close, hands-on way of working to help biotech teams make confident decisions, adapt as programs evolve and stay with one partner from early development through commercialization. With process development, manufacturing, analytics and fill-finish connected under one system, we reduce handoffs, protect continuity and help clients grow without disruption. We were made for this.
For more information or to speak with one of our experts email us at info@53biologics.com